Strategies in Diabetes Treatment: Where Are We?

Diabetes continues to impact millions of Americans and have a profound financial impact on the healthcare system. Over the past 5 years, there has been a shift in the management of type 2 diabetes to focus more on individuals when selecting monitoring parameters, metrics, and certain medications. The American Diabetes Association has updated their guidelines in 2022 to reflect this shift. The guidelines are now more specific in how the management of diabetes should be expanded to include a holistic approach to the management plan. This activity will review and discuss the 2022 ADA guidelines and its recommended patient-centered approach. This activity will include a discussion of continuous glucose monitoring, glucose monitoring metrics and parameters, and updates on the latest information for selected drug classes used for the management of diabetes. Of the classes, SGLT2is and GLP1 agonists will be discussed in depth since recent clinical trials have led the Food and Drug Administration (FDA) to add indications that have prompted the ADA to move these classes to first-line therapy for certain patients with diabetes based on specific comorbidities, such as obesity, HF, CV disease, and CKD.